Compare TITN & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TITN | ADCT |
|---|---|---|
| Founded | 1980 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 416.9M | 484.4M |
| IPO Year | 2007 | 2019 |
| Metric | TITN | ADCT |
|---|---|---|
| Price | $19.81 | $3.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $20.50 | $7.75 |
| AVG Volume (30 Days) | 177.0K | ★ 641.0K |
| Earning Date | 05-21-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,427,107,000.00 | $81,357,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.75 | $66.49 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $13.21 | $1.13 |
| 52 Week High | $21.75 | $4.98 |
| Indicator | TITN | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 66.54 | 49.84 |
| Support Level | $18.73 | $3.41 |
| Resistance Level | $20.65 | $4.71 |
| Average True Range (ATR) | 0.71 | 0.21 |
| MACD | 0.46 | 0.01 |
| Stochastic Oscillator | 87.47 | 66.92 |
Titan Machinery Inc owns and operates a network of full-service agricultural and construction equipment stores. The company sells and repairs agricultural equipment, including machinery and attachments for large-scale farming and home and gardening purposes, as well as construction equipment. It operates through the following segments: The Agriculture segment sells, services, and rents machinery and related parts and attachments, for uses ranging from large-scale farming to home and garden use, The construction segment sells, services, and rents machinery, and related parts and attachments, for uses ranging from heavy construction to light industrial machinery use, and the Europe and Australia segments.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).